uniQure N.V. - 8-K Filing
uniQure submitted a Biologics License Application to the FDA and Marketing Authorisation Application to the UK MHRA for ifezuntirgene inilparvovec (AMT-130) for Huntington’s disease. (Items: 7.01 Regulation FD Disclosure, 9.01 Financial Statements and Exhibits)
Tickers: $QURE